Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region

Next Previous
Trial Profile

A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary) ; Deucravacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms RePhlect
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 27 Sep 2024 According to a Bristol-Myers Squibb Media Release,North American cohort (United States and Canada) data are collected through the CorEvitas Psoriasis Registry, currently enrolling patients across 263 private and academic clinical sites from 596 physicians in 40 states in the United States and seven Canadian provinces. The enrollment of the study began in September 2023.
  • 27 Sep 2024 According to a Bristol-Myers Squibb Media Release, design and conduct of the RePhlect North American cohort study was a collaborative effort between CorEvitas and Bristol Myers Squibb, with financial support for the research provided by Bristol Myers Squibb. The CorEvitas Psoriasis Registry was developed in collaboration with the National Psoriasis Foundation.
  • 27 Sep 2024 According to a Bristol-Myers Squibb Media Release, interim results from this study are being presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands taking place September 25-28, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top